SHAPING THE FUTURE WITH THE SWIRLING FLOW STENT

biomimics-logo

biomimicry

n (Life Sciences & Allied Applications / Biology) the mimicking of life using imitation biological systems

Board

Simon Cartmell

Chairman

With 30 years’ pharmaceutical, biotech and medtech experience gained in commercial, product development, supply chain, strategic leadership and corporate executive roles, Simon is a serial entrepreneur in early stage healthcare businesses. As CEO of ApaTech Ltd, a QMUL spinout, he developed a world leader in orthobiologics prior to its sale to Baxter for $330m in March 2010.Prior to joining ApaTech in 2004 Simon was a Main Board Director of Celltech Group plc, serving as CEO, Celltech Pharmaceuticals, prior to which he served as COO of Vanguard Medica (later Vernalis plc). The early part of his career was spent at Glaxo/Glaxo Wellcome plc in a series of senior UK and international commercial, supply chain and strategic development leadership roles.He is currently a Non-Executive Director of Phase4 Ventures and ReNeuron plc, an advisor to the MTI/University of Manchester Premier Fund and part-time CEO of Calon Cardio-Technology Ltd.


Alan O’Connell

Director

Alan is a Partner at Seroba Life Sciences. Prior to joining Seroba Life Sciences, Alan worked in a variety of product development and business development roles at Elan Corporation (Dublin), American Biogenetic Sciences, Inc. (New York), and the Medicines Control Agency (London). His previous venture capital experience was gained at Estée Lauder Investments (New York) and he still sits on the Lauder Scientific Advisory Board. In addition to Veryan, Alan sits on the boards of Ario Pharma, Opsona, Crescent Diagnostics and Heart Metabolics.


Chas Taylor

CEO, Executive Director

Chas has over 20 years’ experience in the medical device industry. He has been involved in successful medical device start-up companies since 1996. He co-founded embolic filter and carotid stent specialists MedNova which was acquired by Abbott in 2005. Before this he worked with CR Bard for twelve years in various sales, marketing and general management roles. During this time he was based in the USA for eight years in senior positions including Vice-President for Bard Cardiovascular.